Correlation
The correlation between HALO and HROW is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
HALO vs. HROW
Compare and contrast key facts about Halozyme Therapeutics, Inc. (HALO) and Harrow Health, Inc. (HROW).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HALO or HROW.
Performance
HALO vs. HROW - Performance Comparison
Loading data...
Key characteristics
HALO:
0.58
HROW:
0.71
HALO:
1.07
HROW:
1.70
HALO:
1.19
HROW:
1.20
HALO:
0.89
HROW:
0.59
HALO:
2.15
HROW:
1.45
HALO:
14.00%
HROW:
35.52%
HALO:
51.35%
HROW:
82.25%
HALO:
-74.26%
HROW:
-99.46%
HALO:
-20.06%
HROW:
-79.63%
Fundamentals
HALO:
$6.74B
HROW:
$998.23M
HALO:
$3.78
HROW:
-$0.64
HALO:
6.22
HROW:
4.69
HALO:
13.91
HROW:
17.68
HALO:
$1.08B
HROW:
$212.86M
HALO:
$887.05M
HROW:
$158.64M
HALO:
$699.60M
HROW:
$18.65M
Returns By Period
In the year-to-date period, HALO achieves a 17.28% return, which is significantly higher than HROW's -16.21% return. Over the past 10 years, HALO has underperformed HROW with an annualized return of 12.04%, while HROW has yielded a comparatively higher 12.71% annualized return.
HALO
17.28%
-8.71%
16.33%
29.34%
6.84%
18.23%
12.04%
HROW
-16.21%
13.48%
-32.93%
57.57%
57.24%
39.04%
12.71%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HALO vs. HROW — Risk-Adjusted Performance Rank
HALO
HROW
HALO vs. HROW - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Harrow Health, Inc. (HROW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
HALO vs. HROW - Dividend Comparison
Neither HALO nor HROW has paid dividends to shareholders.
Drawdowns
HALO vs. HROW - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum HROW drawdown of -99.46%. Use the drawdown chart below to compare losses from any high point for HALO and HROW.
Loading data...
Volatility
HALO vs. HROW - Volatility Comparison
Halozyme Therapeutics, Inc. (HALO) has a higher volatility of 35.23% compared to Harrow Health, Inc. (HROW) at 19.21%. This indicates that HALO's price experiences larger fluctuations and is considered to be riskier than HROW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
HALO vs. HROW - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Harrow Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. HROW - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a gross profit of 216.46M and revenue of 264.86M. Therefore, the gross margin over that period was 81.7%.
HROW - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Harrow Health, Inc. reported a gross profit of 32.31M and revenue of 47.83M. Therefore, the gross margin over that period was 67.5%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported an operating income of 141.54M and revenue of 264.86M, resulting in an operating margin of 53.4%.
HROW - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Harrow Health, Inc. reported an operating income of -11.23M and revenue of 47.83M, resulting in an operating margin of -23.5%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a net income of 118.10M and revenue of 264.86M, resulting in a net margin of 44.6%.
HROW - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Harrow Health, Inc. reported a net income of -17.78M and revenue of 47.83M, resulting in a net margin of -37.2%.